Burosumab (re-assessment, 50 M € limit exceeded: X-linked hypophosphatemia, patients aged ≥ 1 - < 18 years)

Subject:

• Active Substance: Burosumab
• Name: Crysvita^®
• Therapeutic area: Hypophosphatemia
• Pharmaceutical company: Kyowa Kirin GmbH

Time table:

• Start: 01.02.2022
• Final decision by G-BA: 21.07.2022

Final decision:

• HInt for a non-quantifiable additional benefit